Supreme Court healthcare policy 5th Circuit Court of Appeals FDA approval drug development mifepristone biotech industry medical regulation pharmaceutical law

The biotech industry has long relied on a core principle: FDA-regulated, evidence-based science should determine how medicines reach patients—not litigation. That principle has been repeatedly tested, most notably in a prior Texas case challenging the FDA’s approval of mifepristone, an unprecedented attempt to overturn decades of rigorous scientific review through judicial intervention. Now, that principle faces renewed pressure.

On Friday, the 5th Circuit Court of Appeals reinstated a requirement that mifepristone, a medication used safely by millions for over 20 years, must be dispensed in person. The drug’s manufacturer, Danco, immediately appealed to the Supreme Court. By Monday morning, the Court granted a one-week stay, temporarily halting the order. As a result, mifepristone is once again available via mail and at pharmacies—but its future accessibility remains uncertain.

This legal back-and-forth underscores a growing concern: even long-standing, FDA-approved drugs are now vulnerable to judicial overrides of the agency’s regulatory decisions. The outcome could reshape the landscape for drug development, introducing new risks for biotech companies and patients alike.

Source: STAT News
How one trader used morse code to trick Grok into sending them billions of crypto tokens from its verified wallet
← Previous

How one trader used morse code to trick Grok into sending them billion...

 Texans owner Cal McNair: We're fully committed to C.J. Stroud, will see how contract works out
Next →

Texans owner Cal McNair: We're fully committed to C.J. Stroud, will se...